Sep 10, 2025
Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis
Sep 02, 2025
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 11, 2025
Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress
Aug 01, 2025
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 01, 2025
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 03, 2025
Karyopharm to Present at the Jefferies Global Healthcare Conference
Jun 02, 2025
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 19, 2025
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference
May 12, 2025
Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification
May 08, 2025
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025
May 01, 2025
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 01, 2025
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 03, 2025
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 24, 2025
Karyopharm Announces 1-for-15 Reverse Stock Split
Feb 19, 2025
Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress
Feb 03, 2025
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 13, 2025
Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives
Jan 02, 2025
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 02, 2025
Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer
Dec 09, 2024
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications